BioSpace News Archive

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution.

Kamari Pharma today announced two abstracts reporting results for its novel TRPV3 inhibitors, KM-001(topical) and KM-023 (oral), have been selected for presentation at the 81st Annual Meeting of the Society for Investigative Dermatology (SID), being held May 15-18, 2024 in Dallas, TX, USA.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today provided an update on its solid tumor and heme malignancies clinical programs.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024.

CareDx, Inc. has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close.

INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update.

At this year’s Interphex, ACG Engineering, part of ACG - the world’s only integrated pharmaceutical solutions and manufacturing company - will be focusing on its cost-effective approach to taking generics to market.

The global oncology market size was valued at USD 222.36 billion in 2023 and is poised to grow from USD 242.15 billion in 2024

Olympus announced positive changes to commercial payer policies covering patients who could benefit from the iTind™ procedure, a minimally invasive treatment for the lower urinary tract symptoms caused by benign prostatic hyperplasia, also known as enlarged prostate.